新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 药物递送 » J Control Release:蛙皮凝集素作为药物输送载体研究取得重要进展

J Control Release:蛙皮凝集素作为药物输送载体研究取得重要进展

来源:昆明动物研究所 2011-04-19 15:36

凝集素由于其专一的糖或者糖蛋白结合特性而被认为是合适的药物靶向输送载体,但大部分凝集素分子量大而具有明显毒性或者免疫原性,不适合用于药物靶向。赖仞研究员领导的课题组从蛙皮肤中识别了以小分子量凝集素(Odorranalectin),分子量仅有1700 Da, 具有药物靶向输送载体的潜力(Odorranalectin is a small peptide lectin with potential for drug delivery and targeting.PLoS One. 2008 ;3:e2381.)。最近,赖仞研究员课题组依托复旦大学药学院蒋兴国课题组和沈阳药科大学药学院黄亮课题组将Odorranalectin作为帕金森疾病治疗药物的输送载体,并通过鼻腔给药在疾病动物模型上实验其药物输送和疾病治疗能力,结果显示Odorranalectin可以增强药物输送能力和疾病治疗效果,该工作最近在线发表于国际知名药剂学刊物Journal of Controlled Release,2011 Feb 26, 文章题目为:(Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration)。(生物谷Bioon.com)

生物谷推荐原文出处:

J Control Release. 2011 Feb 26.

Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.

Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L, Zhang Q, Jiang X, Fang L, Lai R.

Department of Pharmaceutical Science, School of Pharmacy, Fudan University, Shanghai 201203, China; Department of Pharmaceutical Science, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning110016, China.

Abstract

Odorranalectin (OL) was recently identified as the smallest lectin with much less immunogenicity than other members of the lectin family. In this study, to improve nose-to-brain drug delivery and reduce the immunogenicity of traditional lectin modified delivery system, OL was conjugated to poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles and its biorecognitive activity on nanoparticles was verified by haemagglutination tests. Nose-to-brain delivery characteristic of OL-conjugated nanoparticles (OL-NP) was investigated by in vivo fluorescence imaging technique using DiR as a tracer. Besides, urocortin peptide (UCN), as a macromolecular model drug, was incorporated into nanoparticles and evaluated for its therapeutic efficacy on hemiparkinsonian rats following intranasal administration by rotation behavior test, neurotransmitter determination and tyrosine hydroxylase (TH) test. The results suggested that OL modification increased the brain delivery of nanoparticles and enhanced the therapeutic effects of UCN-loaded nanoparticles on Parkinson's disease. In summary, the OL-NPs could be potentially used as carriers for nose-to-brain drug delivery, especially for macromolecular drugs, in the treatment of CNS disorders.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库